கட்டி செல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from கட்டி செல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In கட்டி செல் Today - Breaking & Trending Today
E-Mail IMAGE: Zhenyu Yue, PhD, Professor of Neurology and Neuroscience, Director of Basic and Translational Research of Movement Disorders, Icahn School of Medicine at Mount Sinai and senior author of the paper. view more Credit: Mount Sinai Health System Mount Sinai Researchers Find Removal of AKAP11 Protein by Autophagy as a key to Fuel Mitochondrial Metabolism and Tumor Cell Growth through activating protein kinase A (PKA) (Patent pending) Corresponding Author: Zhenyu Yue, PhD, Professor of Neurology, Aidekman Family Professorship, Director of Basic and Translational Research in Movement Disorders, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai. Bottom Line: We uncovered a mechanism that tumor cells exploit selective autophagy for metabolic reprogramming that benefits tumor cell growth and offers resistance to glucose deprivation. Our study suggests that AKAP220-mediated autophagy as a novel therapeutic target for spec ....
Researchers reveal novel therapeutic target in the treatment of certain cancers Mount Sinai Researchers Find Removal of AKAP11 Protein by Autophagy as a key to Fuel Mitochondrial Metabolism and Tumor Cell Growth through activating protein kinase A (PKA) (Patent pending) Corresponding Author: Zhenyu Yue, PhD, Professor of Neurology, Aidekman Family Professorship, Director of Basic and Translational Research in Movement Disorders, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai. Bottom Line: We uncovered a mechanism that tumor cells exploit selective autophagy for metabolic reprogramming that benefits tumor cell growth and offers resistance to glucose deprivation. Our study suggests that AKAP220-mediated autophagy as a novel therapeutic target for specific cancer treatment. ....
Hong Kong unveils next-gen drug for cancers associated with EpsteinâBarr virus Hong Kong unveils next-gen drug for cancers associated with EpsteinâBarr virus 03 March 2021 | News HKBU has established a spin-off company named BP InnoMed Limited (BPI) to further develop this new anti-EBV drug and carry out clinical trials Source: PR Newswire A Hong Kong Baptist University-led (HKBU) research team has developed a novel drug which has the potential to become a next-generation treatment for cancers associated with Epstein–Barr virus (EBV). The peptide-linked drug, which is responsive to the acidic environment found in tumours, is the first known agent to have successfully targeted two viral proteins that are simultaneously produced by EBV. ....